Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 6,000 Ordinary Shares from the GlaxoSmithKline Employee Trust ("GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on January 13, 2006, and the Company was advised of it on January 16, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond this standard employee trust activity are disclosed.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust prior to and after the January 13, 2006 transfer.
- Confirm the specific number of shares allocated to each participant in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand vesting conditions.
- Check for any other concurrent filings regarding director shareholdings for the same period.